NEUROCRINE BIOSCIENCES

Company snapshot

NEUROCRINE BIOSCIENCES maintains 79 tracked programs across Major Depressive Disorder, Schizophrenia, Congenital Adrenal Hyperplasia, Tardive Dyskinesia, Adrenal Insufficiency, Classic Congenital Adrenal Hyperplasia (CAH), CAH - Congenital Adrenal Hyperplasia, Insomnia, Tourette Syndrome, Parkinson's Disease, Movement disorders, Schizophrenia, Schizophrenia. Momentum score: 20/100 (30-day delta: n

• 2 approved product(s) across US/EU regulatory metadata.
• 79 active pipeline program(s) linked via ClinicalTrials.gov.
• 111 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for NEUROCRINE BIOSCIENCES. Not investment advice.

• Peer + 0 momentum

  Vanda Pharmaceuticals Netherlands

  TA overlap score 42

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for NEUROCRINE BIOSCIENCES.

1. Jun 8, 2026 Clinical update

   NBI-74788-CAH3003 — Phase 3

2. Jun 8, 2026 Clinical update

   NBI-1065845-MDD3027 — Phase 3

3. Jun 8, 2026 Clinical update

   NBI-1065845-MDD3026 — Phase 3

4. Jun 8, 2026 Clinical update

   NBI-1065845-MDD3025 — Phase 3

5. Jun 8, 2026 Clinical update

   NBI-1065845-MDD3024 — Phase 3

View all clinical trial activity →

• What is NEUROCRINE BIOSCIENCES?

  NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal Hyperplasia, Tardive Dyskinesia, Adrenal Insufficiency. Nova

• Is NEUROCRINE BIOSCIENCES publicly traded?

  Yes. NEUROCRINE BIOSCIENCES is listed with ticker NBIX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does NEUROCRINE BIOSCIENCES develop or market?

  We link 28 drug profile(s) where NEUROCRINE BIOSCIENCES is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/neurocrine-biosciences-inc#company-drugs.

• What are the latest developments for NEUROCRINE BIOSCIENCES?

  In the last 12 months our linked public records show 79 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does NEUROCRINE BIOSCIENCES focus on?

  NEUROCRINE BIOSCIENCES focuses on Major Depressive Disorder, Schizophrenia, Congenital Adrenal Hyperplasia based on our analysis of their pipeline programs and drug development activities.